decent beat/rais quiet kras-front
remain overweight rate share follow would describ
earn updat right middl fairway though commerci
portfolio saw mix perform post solid top- bottom-lin beat
upward revis made guidanc third time year develop
front expect full clinic updat continu leav
unmodel opportun durabl data lack point nearer-term
look close otezla acquisit anticip addit updat
quarter bite platform remain buyer
highest qualiti beat beat report top- bottom-
line beat total revenu vs consensu pjc non-
gaap ep consensu pjc put take across
commerci portfolio includ miss aimovig beat
biosimilar product revenu beat consensu pjc
revenu guidanc rais previous
consensu ep guidanc increas
midpoint previous consensu base
new guidanc tweak estim chang price target
expect data-rich year updat world
lung esmo last quarter manag confirm well wait
next clinic updat enrol continu nsclc monotherapi
studi highlight cohort patient enrol
monotherapi trial target dose initi result expect guid
forward develop path indic reiter expect
fair amount biomark data next year expect clarifi molecular
signatur could predict patient respons therapi howev get
fulsom durabl data remain unmodel opportun
continu recommend share drop late call note plan
end neurosci research earli develop program view
posit given uncertainti pathogenesi biolog basi
larg neurolog indic beyond expect otezla acquisit close
anticip clinic updat oncolog portfolio includ
egfrviii bite gbm hle-bit aml remain buyer
global biopharmaceut compani
price close octob
ep discount
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
page
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
total aimovig revenu
dollar except per share data
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
